Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

Eidos hits new peak on Phase II extension readout in amyloidosis
Eidos Therapeutics Inc. (NASDAQ:EIDX) shares climbed $8.47 (18%) to $55.02, touching an all-time intraday high of $55.25, after the company said results of a Phase II open-label extension trial to treat transthyretin amyloidosis cardiomyopathy

Read the full 440 word article

User Sign In